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Edited by Jesus AvilaAbstract Immunization against the Ab peptide reverses the
pathologic and behavioral manifestations of Alzheimers disease
in murine models. Since active immunization is associated with
an autoimmune meningoencephalitis in a subset of humans, pas-
sive transfer of anti-Ab immunoglobulin is being pursued as a
potentially safer alternative. We have identiﬁed cases of menin-
goencephalitis subsequent to peripheral and intracerebral passive
immunization of Tg2576 mice. The vasocentric mononuclear
inﬁltrate localized only to brain regions aﬀected by Ab amyloid
deposits suggesting that the inﬂammatory reaction was Ab spe-
ciﬁc. This report indicates that current passive immunization in
humans should proceed with careful regard for autoimmune com-
plications.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The cerebral accumulation of the hydrophobic peptide,
Ab, is an invariant feature of Alzheimers disease (AD) [1].
Immune-based therapies directed against the Ab peptide
have been shown in transgenic murine models to ameliorate
Ab amyloid pathology and reverse cognitive behavioral def-
icits [2–6]. Based in part on the successful clearance of Ab
and the lack of toxicity in murine models, human clinical
trials were performed using an active immunization para-
digm. However, a major side eﬀect of active immunization
with Ab42 in humans is the development of an aseptic, vaso-
centric meningoencephalitis in a subset of patients [7,8]. As a
result, passive immunization with anti-Ab monoclonal anti-
bodies is currently being pursued as a potentially safer
alternative.
While the mechanism underlying the inﬂammatory reaction
in humans has not been completely elucidated, the predomi-
nance of T cells in cerebral inﬁltrates suggested that a cell-
mediated autoimmune response was responsible for theAbbreviations: AD, Alzheimers disease; CNS, central nervous system
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doi:10.1016/j.febslet.2005.03.070development of meningoencephalitis [7]. Furthermore, the
development of meningoencephalitis did not correlate with
ELISA titers for anti-Ab antibodies, suggesting that humoral-
mediated autoimmunity was not involved in the pathogenesis
of autoimmunity upon active immunization with Ab42 [8].
Autoimmune reactions to active or passive anti-Ab immuno-
therapy in murine models have not been reported. Here, we re-
port the development of meningoencephalitis in the Tg2576
model of Alzheimers amyloidosis upon passive immunization
with an anti-Ab monoclonal antibody.2. Materials and methods
2.1. Peripheral immunization
Tg2576 mice overexpressing human APP harboring the Swedish
mutation [9] were maintained on a C57B6/SJL F2 background by suc-
cessive backcrossing to wild-type C57B6/SJL F1 females. All mice were
generated and handled according to University of Pennsylvania Insti-
tutional Animal Care and Use Committee guidelines. Wild-type and
transgenic littermates were administered an initial dose of 400 lg of
protein G-puriﬁed NAB61, an anti-Ab mouse monoclonal antibody
generated in our laboratory using nitrated Ab as immunogen, or
non-speciﬁc mouse IgG (Sigma, St. Louis, MO) intraperitoneally on
day 1, followed by maintenance doses of 200 lg on days 4, 10 and 16.
2.2. Intracerebral immunization
Six- to twelve-month old Tg2576 mice or Tg2576/PS-1P246L/+ mice
generated from crossing heterozygous Tg2576 mice with mice hetero-
zygous for the P246L PS-1 familial AD mutation [10] were used. Fif-
teen mice received stereotaxic intracerebral injections of NAB61
(n = 8) or non-speciﬁc mouse IgG (n = 7) with a 33-gauge Hamilton
syringe (Hamilton, Reno, NV) into the left hippocampus at one of
the following two coordinates with respect to bregma: 2.7 mm pos-
terior, +2.5 mm lateral, and 3.0 mm ventral; 2.3 mm posterior,
+2.0 mm lateral, and 1.8 mm ventral. Mice received 2–4 lg of immu-
noglobulin and were sacriﬁced 3–7 days post-treatment.
2.3. Immunohistochemistry and histology
Following completion of the immunization protocols, mice were
deeply anesthetized and transcardially perfused with heparinized
PBS. Brains were removed and immersion ﬁxed in 10% neutral buf-
fered formalin. Samples were dehydrated through a series of graded
ethanol solutions to xylene, and inﬁltrated with paraﬃn as described
[11]. Six micrometer-thick sections were immunostained using stan-
dard avidin-biotin-peroxidase methods with 3-3 0diaminobenzedene.
Rat anti-mouse Mac-3 (BD Biosciences Pharmingen, San Diego,
CA), rat anti-mouse CD45R/B220 (BD Biosciences Pharmingen) and
rat anti-human CD3 (MCA1477; Serotec, Oxford, UK) were used as
primary antibodies in addition to anti-Ab antibodies to visualize Ab
deposits. To detect mouse immunoglobulin, the primary antibody
was omitted. Species-speciﬁc HRP-conjugated anti-immunoglobulinblished by Elsevier B.V. All rights reserved.
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ondary antibodies. Routine histochemistry was also performed using
hematoxylin and eosin, and thioﬂavin S.Fig. 2. Region-speciﬁc meninoencephalitis. Sections from various
brain regions were stained with hematoxylin and eosin. Mononuclear
inﬁltrates were observed in regions aﬀected by Ab amyloid pathology3. Results
A novel, Ab-speciﬁc monoclonal antibody, NAB61, was
developed for a passive immunization trial. NAB61 recognizes
mature senile plaques and amyloid angiopathy in aﬀected AD
and transgenic mouse brain sections (Fig. 1). No staining with
NAB61 was seen in non-pathologic human and murine tissue.
A short immunization schedule was followed in which a cohort
of 18–19-month old APP transgenic mice [9] were injected
intraperitoneally with 400 lg of NAB61 (N = 21) or non-spe-
ciﬁc murine IgG (N = 17), followed by booster immunizations
of 200 lg on days 4, 10 and 16. As this was a pilot trial of this
procedure, the mice reported here were sacriﬁced on day 20 for
pathologic analysis.
Although, an autoimmune inﬂammatory response has not
been described for transgenic murine models of intraparen-
chymal brain Ab deposits, the complications encountered
upon active immunization in humans prompted a thorough
pathologic evaluation for complications secondary to passive
immunization. Out of 21 transgenic mice immunized with
NAB61, one case of meningoencephalitis was identiﬁed.
Hematoxylin and eosin staining of sections taken throughout
the central nervous system (CNS) demonstrated the presence
of small, mononuclear inﬂammatory cells aﬀecting the lepto-
meninges overlying regions which display Ab pathology
including the olfactory bulb, neocortex and hippocampus
(Fig. 2, arrowheads). Consistent with an autoimmune inﬂam-
matory response, follicular aggregates with apparent germinalFig. 1. NAB61 recognizes senile plaques and amyloid angiopathy.
NAB61 is an Ab-speciﬁc mouse monoclonal antibody which recog-
nizes pathologic Ab deposits by immunohistochemistry. Brain sections
of Tg2576 brain (top) and AD brain (bottom) were stained with
NAB61 demonstrating speciﬁc staining of amyloid plaques and
amyloid angiopathy. No NAB61 immunostaining was present in
sections from unaﬀected human brain, non-transgenic mouse brain,
and young Tg2576 mouse brains prior to onset of Ab amyloid plaques
(data not shown). Scale bars, 20 lm.
including the (A) olfactory bulbs, (B) cortex and hippocampus. Other
regions, such as the (C) striatum, (D) cerebellum, (E) brainstem and
(F) spinal cord were generally free of inﬂammatory cells. No
polymorphonuclear lymphocytes were observed. Arrowheads point
to the extensive leptomeningeal involvement. Arrows point to amyloid
plaques. Scale bars, 300 lm.centers could be identiﬁed within the leptomeninges (Fig. 3).
Furthermore, the absence of polymorphonuclear lymphocytes
indicated that no acute inﬂammatory component was present.
The inﬂammatory response extending along blood vessels
also disrupted the blood–brain barrier, as evidenced by in-
creased immunoreactivity for endogenous mouse immuno-
globulin throughout the parenchyma of the brain subjacent
to aﬀected blood vessels (Fig. 4). Finally, the inﬂammatory
response also involved the parenchyma, manifested as a vaso-
centric mononuclear inﬁltrate (Fig. 5). Regions without abun-
dant Ab pathology such as the striatum, cerebellum,
brainstem and spinal cord were generally not aﬀected (Fig.
2). Furthermore, no inﬂammatory response has been identi-
ﬁed in transgenic mice treated with non-speciﬁc IgG
(N = 17), or non-transgenic mice treated with NAB61
(N = 10), suggesting that the meningoencephalitis was speciﬁc
to NAB61 treatment in animals containing Ab amyloid
pathology.
To further deﬁne the inﬂammatory response, immunohisto-
chemistry for Mac3, CD3 and CD45R was performed to iden-
tify macrophages, T cells and B cells, respectively (Fig. 3). In
contrast with the described case from the human immunization
Fig. 3. Mononuclear lymphocytic chronic inﬂammation. Immunohis-
tochemical detection of inﬂammatory inﬁltrates was conducted using
antibodies that recognize CD3, CD45R andMac3 which demonstrated
the presence of T cells, B cells and macrophages, respectively. The
bottom panel shows an example of the follicular aggregates of
lymphocytes forming apparent germinal centers within the leptome-
ninges.
Fig. 4. Disruption of the blood–brain barrier. Direct detection of
immunoglobulin using HRP-conjugated anti-mouse IgG resulted in
diﬀuse DAB staining within the brain parenchyma of the mouse
aﬀected by meningoencephalitis (right). Unaﬀected mice showed little
to no parenchymal staining for immunoglobulin (left). Nuclei are
stained blue with a hematoxylin counterstain. Arrowheads point to
inﬂammatory inﬁltrates which track with vascular structures. The
arrow points to a follicular aggregate of lymphocytes. Scale bars,
200 lm.
Fig. 5. Vasocentric mononuclear inﬁltration. Sections were stained
with Thioﬂavin S for Ab amyloid (green) and counterstained with
DAPI for nuclei (blue). Mononuclear inﬁltrates were associated with
amyloid-laden blood vessels in both the meninges and within the
cortical parenchyma (top panels). Direct detection of immunoglobulin
using HRP-conjugated anti-mouse IgG demonstrated the presence of
immunoglobulin deposits (brown) in aﬀected meningeal and cortical
vasculature (bottom panels, with a hematoxylin counterstain for
nuclei).
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nantly comprised of B cells, although macrophages and T cells
were also present.Since NAB61 was administered via the peripheral circula-
tory system, we analyzed the meningeal and intraparenchymal
vasculature of aﬀected brain regions. Vasocentric lymphocytic
inﬁltration was often centered around blood vessels containing
amyloid angiopathy (Fig. 5, top panels), as determined by Thi-
oﬂavin S staining for amyloid. Furthermore, aﬀected blood
vessels contained immunoglobulin deposits as determined by
immunohistochemistry (Fig. 5, bottom panels). These ﬁndings
suggest that immunoglobulin deposition within amyloid laden
blood vessels may serve as a nidus for an autoimmune inﬂam-
matory response.
In addition to the systemic passive immunization trials,
intracerebral injections of NAB61 were performed in trans-
genic mice. Out of 8 mice which received intrahippocampal
injections of NAB61 (2–4 lg), two had signiﬁcant inﬁltrates
in close proximity to the injection track. Similar to the case
identiﬁed after peripheral immunization, hematoxylin and eo-
sin staining demonstrated perivascular mononuclear inﬁltrates
which were immunoreactive for macrophage, T lymphocyte
and B lymphocyte markers (Fig. 6). Mac3-positive macro-
phages were also found along the length of the cortical needle
track. Inﬁltrates were not observed in the contralateral hemi-
sphere or sections of cortex distant to the injection track,
and polymorphonuclear inﬂammatory cells were not present.
In contrast, no inﬂammation could be identiﬁed by hematoxy-
lin and eosin staining of mice injected with non-speciﬁc IgG
(n = 7). However, immunohistochemical staining of IgG-
injected mice did show macrophages along the injection track
consistent with the typical reaction to a stab wound. Lympho-
cytes were generally absent, with the exception of two mice
Fig. 6. Inﬂammation with intracerebral NAB61 injection. Tg2576 and
Tg2576/PS-1P246L/+ mice showed leptomeningeal, vasocentric, mono-
nuclear inﬁltrates as determined by hematoxylin and eosin (H&E)
staining after intrahippocampal injection of NAB61. Additional
immunostaining for CD3, CD45R and Mac3 demonstrated the
presence of T cells, B cells and macrophages, respectively. Scale bars,
50 lm.
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cular cuﬃng, perhaps representing a low-level non-speciﬁc re-
sponse to the trauma of intracerebral injection with
immunoglobulin. However, signiﬁcant lymphocytic inﬁltration
could only be identiﬁed in mice passively immunized with
NAB61.4. Discussion
The development of meningoencephalitis in 6% of individu-
als immunized with Ab42 halted a phase II human AD clinical
trial. This adverse event calls into question the safety of active
immunization for the treatment of AD [7,8]. Anti-Ab immuno-
therapy-induced meningoencephalitis appears to be due to the
aberrant activation of a deleterious T cell response that can
compromise blood vessel integrity. Furthermore, it does not
correlate with the presence of anti-Ab antibodies as deter-mined by ELISA titers [8]. Therefore, administration of anti-
Ab antibodies could be a safer alternative to active Ab immu-
nization for the treatment of AD.
This is the ﬁrst report of meningoencephalitis in APP trans-
genic mice that model brain parenchyma deposits of Ab upon
active or passive immunization. The Tg2576 transgenic mice
used in this study were maintained on a mixed C57B6 · SJL
background and, therefore, display considerable haplotype
heterogeneity which might account for the variable and infre-
quent occurrence of the adverse consequence of passive immu-
nization described here. Further investigation is necessary to
better understand the mechanisms underlying the variable pen-
etrance of autoimmunity in both mice and humans.
Multiple mechanisms may be responsible for inﬂammatory
changes after active or passive Ab immunization. The patho-
logic ﬁndings of passive immunization described in this report
are consistent with an inﬂammatory mechanism triggered by
antibody binding to Ab amyloid angiopathy. Such binding
may enhance antigen presentation of Ab resulting in activation
of reactive T cells. Alternatively, immunoglobulin deposition
may lead to local disruption of the blood–brain barrier where-
by antigens normally sequestered in the CNS are presented to
the immune system, triggering a more generalized autoimmune
response. In support of the latter hypothesis, the incidence of
intracerebral hemorrhage is increased in APP transgenic mice
with prominent Ab vascular amyloid deposits that resemble
congophilic angiopathy upon passive immunization with
anti-Ab antibodies [12]. Furthermore, we found that direct
inoculation of the CNS with NAB61 resulted in perivascular
inﬂammation. In either situation, humoral and cellular-based
immunity cannot be clearly segregated into isolated systems.
Indeed, autoantibodies have been demonstrated to exacerbate
the development of type 1 diabetes which is typically
considered to be a T cell mediated autoimmune disease [13],
suggesting that the humoral and cellular components of auto-
immunity can be interdependent.
Regardless of the mechanism, any immunologic approach to
therapy should be undertaken with careful regard towards un-
wanted complications such as those reported here. An autoim-
mune response to active immunization with Ab42 resulted in
adverse events in clinical trial subjects despite the fact that sim-
ilar adverse eﬀects had not been described for active immuni-
zation in murine models. Given the current attempts at
passive immunization for the treatment of AD in humans,
the presence of aseptic autoimmune meningoencephalitis in a
murine model of Alzheimers Ab amyloidosis warrants careful
monitoring for similar complications in humans.
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